Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01487681|
Recruitment Status : Unknown
Verified December 2011 by Xing Xie, MD, Zhejiang University.
Recruitment status was: Recruiting
First Posted : December 7, 2011
Last Update Posted : December 7, 2011
Human papilloma virus (HPV) infection contributes as a main causative factor to the development of invasive cervical cancer (ICC) and its precursors (cervical intraepithelial neoplasia, CIN). Currently, two prophylactic vaccines are employed for the prevention of genital HPV infection. As the prophylactic efficacy is type-restricted, determining the type-specific HPV distribution and their associations with ICC and its precursors would provide essential information in assessment of HPV vaccination program impact. The baseline information is also important for monitoring possible changes in type-specific HPV distribution after vaccination has been introduced.
Prevalence of HPV infection varies considerably across the world, and data were limited from less-developed countries. Knowledge of the detail pattern of HPV type-specific distribution in each region will be essential for public health policy decisions. This will also form the basis for determining which types should be included in future generation HPV vaccines targeted to specific regions.
While most studies were focus on ICC and high-grade cervical lesions, the association between HPV types and the progression of CIN1 has rarely been studied. CIN1 is an insensitive histopathological sign of HPV infection, most of which will spontaneously regress to normal with host immune system. However, some genotypes have been described as being more persistent and associated with progression from low-grade lesions to high-grade lesions, even ICC. Geographical data on type-specific prevalence of HPV in CIN1 with appropriately designed prospective studies would be helpful in identifying types preferentially associated with progression to malignancy and accurately predicting the future impact of vaccination in specific regions.
Free vaccination supported by the government appears to be unlikely at present in China. Thus, individuals need to pay the cost of vaccines for themselves presently. Yangtze River Delta Area is the most economically developed regions in China, and people here may become the largest vaccinated population at their own expense in China. To the best of the investigators knowledge, no multi-center study on HPV type-specific distribution and their associations with ICC and its precursors is available in Yangtze River Delta Area, China, which highlights the need for timely study in this region before large scale vaccination programs are carried out.
|Condition or disease|
|Human Papilloma Virus Cervical Cancer Cervical Intraepithelial Neoplasia|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||4000 participants|
|Official Title:||Prevaccination Distribution of Cervical Human Papillomavirus (HPV) Types and Their Associations With Invasive Cervical Cancer and Its Precursors in Yangtze River Delta Area, China|
|Study Start Date :||November 2011|
|Estimated Primary Completion Date :||October 2012|
|Estimated Study Completion Date :||October 2013|
|Invasive cervical cancer|
|Cervical intraepithelial neoplasia 2/3|
|Cervical intraepithelial neoplasia 1|
- Percentage of each HPV type in patients with invasive cervical cancer, cervical intraepithelial neoplasia 2-3 and cervical intraepithelial neoplasia 1, respectively, in Yangtze River Delta Area, China [ Time Frame: One year ]
- HPV types significantly associated with persistence or progression of cervical intraepithelial neoplasia 1 at one year in Yangtze River Delta Area, China [ Time Frame: One year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01487681
|Contact: Xing Xie, Professorfirstname.lastname@example.org|
|Women's hospital, School of medicine, Zhejiang University||Recruiting|
|Hangzhou, Zhejiang, China, 310006|
|Contact: Xing Xie, Professor 86-571-87061501 email@example.com|
|Study Director:||Xing Xie, Professor||Women's Hospital School Of Medicine Zhejiang University|